Roumell Asset Management’s CollPlant Biotechnologies CLGN Stock Holding History

Roumell Asset Management’s Portfolio CLGN Stock Details CLGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$1.37M	Sell	27,643 -3,886	-12%	-$216K	2.57%	14
2024 Q1	$1.7M	Sell	31,529 -11,735	-27%	-$635K	3.2%	12
2023 Q4	$2.76M	Sell	43,264 -14,527	-25%	-$795K	5.94%	9
2023 Q3	$3.25M	Hold	57,791	–	–	6.54%	6
2023 Q2	$4.69M	Hold	57,791	–	–	9.21%	2
2023 Q1	$4.06M	Sell	57,791 -2,753	-5%	-$270K	9.19%	2
2022 Q4	$5.06M	Hold	60,544	–	–	12.52%	2
2022 Q3	$4.14M	Hold	60,544	–	–	8.96%	4
2022 Q2	$4.93M	Buy	60,544 +778	+1%	+$71.5K	9.6%	4
2022 Q1	$6.84M	Buy	59,766 +10,198	+21%	+$1.12M	11.05%	3
2021 Q4	$8.11M	Sell	49,568 -6,735	-12%	-$1.2M	10.81%	3
2021 Q3	$9.5M	Hold	56,303	–	–	12.59%	3
2021 Q2	$11.9M	Buy	+56,303	New	+$9M	13.95%	1

Other funds holding CLGN

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

BFEC

Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

RWMG

Redwood Wealth Management Group Medford, New Jersey $232M AUM 22.66% 1-Year Est. Return

Roumell Asset Management's CLGN Position: Q2 2024 in Review

Roumell Asset Management reduced its CollPlant Biotechnologies (CLGN) stake by 12% in Q2 2024, selling an estimated $216K and leaving 27,643 shares worth $1.37M. The position accounts for 2.57% of the portfolio, ranked #14.

Roumell Asset Management first reported a position in CLGN in Q2 2021 and has held it in 13 quarters since. The position peaked at $11.9M in Q2 2021. 14 funds tracked by Wall St. Rank hold CLGN as of Q2 2024.

Roumell Asset Management held 27,643 shares of CollPlant Biotechnologies worth $1.37M as of Q2 2024.
Roumell Asset Management sold 3,886 CollPlant Biotechnologies shares in Q2 2024, an estimated $216K.
CollPlant Biotechnologies made up 2.57% of Roumell Asset Management's portfolio in Q2 2024, its #14 holding.
Roumell Asset Management first reported a position in CollPlant Biotechnologies in Q2 2021 and has held it in 13 quarters since.
Roumell Asset Management's CollPlant Biotechnologies position peaked at $11.9M in Q2 2021.
14 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q2 2024.

Based on Roumell Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.